Sign inCreate account

Report workspace tools

NCT04640311COMPLETEDanonymous

A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Daprodustat

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

Daprodustat

Source & freshness

Source record

NCT ID

NCT04640311

Original source

ClinicalTrials.gov

Source last updated

Apr 10, 2025

Ingested at

May 31, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04640311

Title

A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

PHASE1

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Daprodustat

Target normalized

Daprodustat

Interventions

Daprodustat

Public preview

Source record

This clinical trial, sponsored by GlaxoSmithKline, evaluated the bioequivalence and dissolution of Daprodustat formulations produced by two different manufacturing processes in healthy adult volunteers. The study included 259 participants and was completed in May 2021.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Two-part, Randomized, Double-blind, Single-dose, Crossover Study to Compare Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Adult Volunteers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04640311

Status

COMPLETED

Phase

PHASE1

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

This clinical trial, sponsored by GlaxoSmithKline, evaluated the bioequivalence and dissolution of Daprodustat formulations produced by two different manufacturing processes in healthy adult volunteers. The study included 259 participants and was completed in May 2021.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 10, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04640311

Indication

Anaemia

Modality

small molecule

Target

Daprodustat

Intervention

Daprodustat

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.